No Data
No Data
Pfizer Sticks to 2025 Profit View as It Shrugs off Plunging Paxlovid Sales for COVID
Pfizer's Mixed Q1 Results and Uncertain Long-Term Prospects Justify Hold Rating
Dow Surges 300 Points Amid Trade Deal Hopes: Greed Index Remains In 'Fear' Zone
Asthma and HIV drugs drive performance growth. GlaxoSmithKline (GSK.US) Q1 profits exceeded expectations, maintaining the annual performance outlook.
The company's profits in the first quarter exceeded expectations, particularly strong sales of asthma and HIV treatment drugs offset the negative impact of the overall vaccine Business line sales performance being below expectations.
Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance
Is it all Trump's fault for wildly swinging the 'tariff club'? Pfizer: Uncertainty has hindered manufacturing and research and development investment.
① Pfizer CEO Albert Bourla stated that the uncertainty surrounding Trump's proposed pharmaceutical tariffs is hindering the company's manufacturing and R&D investments in the USA; ② Bourla emphasized that the company hopes to see "certainty," meaning clear tariffs or additional incentives, to increase investment in the USA.